John R. Mascola
#71,129
Most Influential Person Now
Researcher
John R. Mascola's AcademicInfluence.com Rankings
John R. Mascolabiology Degrees
Biology
#3259
World Rank
#5005
Historical Rank
Virology
#68
World Rank
#71
Historical Rank
Immunology
#157
World Rank
#165
Historical Rank
Molecular Biology
#335
World Rank
#341
Historical Rank
Download Badge
Biology
John R. Mascola's Degrees
- Masters Molecular Biology Stanford University
Why Is John R. Mascola Influential?
(Suggest an Edit or Addition)According to Wikipedia, John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center , part of the National Institute of Allergy and Infectious Diseases , National Institutes of Health . He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.
John R. Mascola's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (2020) (5634)
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) (2366)
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 (2010) (1653)
- Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies (2000) (1364)
- Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 (2010) (1115)
- Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies (2005) (1107)
- Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 (2021) (1071)
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 (2021) (1004)
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (2013) (940)
- Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals (2009) (869)
- SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness (2020) (846)
- Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies (1999) (838)
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 (2011) (827)
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (2020) (809)
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibody (2012) (804)
- Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing (2011) (730)
- Structure and immune recognition of trimeric prefusion HIV-1 Env (2014) (682)
- Human skin Langerhans cells are targets of dengue virus infection (2000) (680)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (2014) (675)
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (2020) (613)
- Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies (2009) (610)
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. (2013) (536)
- The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression (1997) (505)
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (2021) (505)
- Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection (2015) (501)
- Gene transfer in humans using a conditionally replicating lentiviral vector (2006) (498)
- Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope (2004) (492)
- Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. (1996) (479)
- Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? (2009) (476)
- Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. (2012) (469)
- HIV‐1 neutralizing antibodies: understanding nature's pathways (2013) (455)
- The role of antibodies in HIV vaccines. (2010) (429)
- Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors (2011) (420)
- Broad HIV-1 neutralization mediated by CD4-binding site antibodies (2007) (420)
- Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface (2014) (416)
- A strategic approach to COVID-19 vaccine R&D (2020) (411)
- Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys (2006) (402)
- Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. (2013) (381)
- Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection (2015) (380)
- Antibody responses to envelope glycoproteins in HIV-1 infection (2015) (373)
- Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C (2008) (369)
- Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. (2014) (365)
- Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G (2016) (355)
- Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies (2008) (348)
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. (2016) (344)
- Rapid development of a DNA vaccine for Zika virus (2016) (340)
- Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization (2021) (333)
- Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 (2009) (332)
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody (2016) (329)
- Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. (2006) (328)
- Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables (2009) (326)
- Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning (2013) (324)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge (2014) (318)
- Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. (2013) (308)
- Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 (2009) (307)
- Crystal structure, conformational fixation, and entry-related interactions of mature ligand-free HIV-1 Env (2015) (305)
- Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection (2014) (302)
- Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques (2014) (297)
- Enhanced neonatal Fc receptor function improves protection against primate SHIV infection (2014) (282)
- A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges (2016) (279)
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (2021) (278)
- Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals (2008) (278)
- Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. (2016) (276)
- Evaluation of candidate vaccine approaches for MERS-CoV (2015) (275)
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates (2021) (270)
- Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 (2013) (267)
- Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody (2016) (260)
- Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors (2015) (260)
- Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies (2014) (259)
- Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody (2016) (259)
- Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines (2005) (255)
- The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes (2003) (249)
- Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo (2014) (243)
- Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies (2013) (242)
- Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses (2016) (241)
- Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells (2005) (241)
- The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region (2001) (240)
- Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 (2011) (240)
- HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. (2018) (239)
- Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination (2016) (236)
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial (2008) (236)
- Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains (2020) (235)
- Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops (2012) (235)
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site (2015) (234)
- Differential Susceptibility to Human Immunodeficiency Virus Type 1 Infection of Myeloid and Plasmacytoid Dendritic Cells (2005) (233)
- Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 (2010) (232)
- Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor (2014) (228)
- Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial (2013) (226)
- Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. (2006) (224)
- Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques (2017) (216)
- Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults (2015) (214)
- Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial (2014) (213)
- Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization (2013) (210)
- Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection (2015) (210)
- Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials (2017) (210)
- Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin (1995) (209)
- A method for identification of HIV gp140 binding memory B cells in human blood. (2009) (209)
- Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 (2018) (208)
- Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys (2011) (204)
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (2022) (202)
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. (2010) (202)
- Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. (1998) (201)
- Monoclonal Antibodies for Prevention and Treatment of COVID-19. (2020) (200)
- The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. (2012) (200)
- Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Δ32 (1998) (196)
- Chimpanzee Adenovirus Vector Ebola Vaccine (2017) (192)
- Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals (2011) (190)
- Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies (2015) (190)
- DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials (2011) (189)
- Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. (2016) (188)
- New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency (2015) (187)
- Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors (2009) (186)
- Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies (2015) (179)
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (2021) (176)
- Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies (2017) (176)
- In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies (2021) (175)
- Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial (2013) (173)
- Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires (2016) (173)
- Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants (2006) (171)
- A proof of concept for structure-based vaccine design targeting RSV in humans (2019) (170)
- Human dendritic cells as targets of dengue virus infection. (2001) (166)
- A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. (2007) (166)
- Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. (2011) (165)
- Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. (2007) (165)
- Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. (1994) (164)
- Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design (2012) (161)
- Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2018) (160)
- A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates (2005) (159)
- Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques (2016) (153)
- Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design (2015) (152)
- Red man syndrome: incidence, etiology, and prophylaxis. (1991) (152)
- Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. (1995) (150)
- Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. (2021) (148)
- Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. (2017) (148)
- Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses (2010) (147)
- Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates (2005) (146)
- Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults (2018) (145)
- Detection of diverse HIV-1 genetic subtypes in the USA (1995) (144)
- Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV (2013) (143)
- Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape (2018) (142)
- Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys (2004) (142)
- Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site (2015) (140)
- Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies (1994) (139)
- Mining the antibodyome for HIV-1–neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains (2013) (139)
- Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes (1999) (138)
- SARS-CoV-2 Viral Variants-Tackling a Moving Target. (2021) (137)
- Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12 (1997) (137)
- Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection (2016) (136)
- Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site (2009) (136)
- Defining the protective antibody response for HIV-1. (2003) (136)
- Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys (2005) (134)
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants (2021) (133)
- Next-generation influenza vaccines: opportunities and challenges (2020) (131)
- PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4 (2012) (130)
- Pathogenicity of Simian-Human Immunodeficiency Virus SHIV-89.6P and SIVmac Is Attenuated in Cynomolgus Macaques and Associated with Early T-Lymphocyte Responses (2005) (130)
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants (2021) (130)
- HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies (2015) (129)
- A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. (2011) (129)
- The Development of CD4 Binding Site Antibodies during HIV-1 Infection (2012) (129)
- Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies (2017) (128)
- SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness (2020) (128)
- LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection (2020) (127)
- Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization (2021) (126)
- Use of broadly neutralizing antibodies for HIV‐1 prevention (2017) (124)
- A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B (1995) (124)
- Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel (2000) (123)
- Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells (2002) (122)
- HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. (1998) (122)
- Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion (2000) (120)
- Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. (2013) (119)
- Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes (2014) (117)
- Isolation of human monoclonal antibodies from peripheral blood B cells (2013) (117)
- Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity (2007) (117)
- Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. (2002) (116)
- Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. (2014) (115)
- Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region (2009) (115)
- Drug Resistance Patterns, Genetic Subtypes, Clinical Features, and Risk Factors in Military Personnel with HIV-1 Seroconversion (1999) (115)
- Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160 (1997) (114)
- The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope (2004) (113)
- Accelerated COVID-19 vaccine development: milestones, lessons, and prospects (2021) (111)
- High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site (2012) (111)
- Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins (2005) (110)
- Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region (2009) (110)
- Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection (2015) (109)
- Multiple roles for HIV broadly neutralizing antibodies (2019) (108)
- Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial (2014) (107)
- Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. (2006) (106)
- Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail (2017) (105)
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial (2015) (103)
- Potent and broad HIV-neutralizing antibodies in memory B cells and plasma (2017) (101)
- Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4+ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding (2012) (101)
- Quadrivalent influenza nanoparticle vaccines induce broad protection (2021) (101)
- Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env (2015) (100)
- Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. (2005) (99)
- Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. (1993) (99)
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron (2022) (98)
- Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates (2010) (98)
- Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry (1995) (97)
- Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism (1997) (96)
- Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial (2017) (96)
- Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. (2006) (96)
- Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment (2009) (96)
- Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells (1998) (93)
- Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection (2015) (93)
- Immunologic and virologic events in early HIV infection predict subsequent rate of progression. (2010) (92)
- Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection (2015) (92)
- Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies (2011) (92)
- De novo identification of VRC01 class HIV-1–neutralizing antibodies by next-generation sequencing of B-cell transcripts (2013) (91)
- Glycan Masking Focuses Immune Responses to the HIV‐1 CD4‐Binding Site and Enhances Elicitation of VRC01‐Class Precursor Antibodies (2018) (91)
- Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions (2007) (90)
- Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site (2012) (90)
- Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge (2017) (90)
- Functional Interrogation and Mining of Natively-Paired Human VH:VL Antibody Repertoires (2017) (89)
- HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. (2005) (89)
- Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529 (2017) (89)
- Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. (2019) (89)
- An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. (2014) (88)
- Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. (2017) (87)
- Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. (2007) (87)
- Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline (2014) (87)
- Multiple introductions of HIV-1 subtype E into the western hemisphere (1995) (86)
- Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV (2016) (85)
- Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability (2019) (84)
- The quest for an antibody‐based HIV vaccine (2017) (84)
- Activation and lysis of human CD4 cells latently infected with HIV-1 (2015) (84)
- Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials (2017) (83)
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants (2022) (82)
- Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort (2003) (82)
- A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies (2012) (82)
- Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. (2012) (81)
- B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4 (2008) (81)
- Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization (2015) (81)
- Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts. (1997) (79)
- Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein (1996) (79)
- Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (2019) (78)
- Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization (2019) (78)
- Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys (2011) (78)
- Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. (1996) (78)
- Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 (2021) (77)
- Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. (2016) (76)
- Particulate Array of Well‐Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach (2017) (76)
- Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles (2020) (75)
- Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies (2014) (75)
- Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa (1996) (74)
- Vaccines for the prevention of HIV-1 disease. (2001) (73)
- HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes (2012) (73)
- Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. (2018) (73)
- Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. (2008) (72)
- Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide (2017) (72)
- Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization (2015) (72)
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (72)
- Novel vaccine technologies for the 21st century (2019) (71)
- Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages (2019) (71)
- Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans (2017) (70)
- Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope (2004) (70)
- Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope (2019) (69)
- Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. (2004) (69)
- Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations (2017) (68)
- Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity (2017) (67)
- Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles (2020) (67)
- Somatic Populations of PGT135–137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics (2012) (66)
- Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. (2019) (66)
- Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization (2021) (66)
- The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates (2021) (65)
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron (2022) (65)
- DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial (2013) (65)
- Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. (2015) (65)
- Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections (2018) (65)
- Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. (2007) (64)
- Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus Challenge (2006) (64)
- Virus‐like Particles Identify an HIV V1V2 Apex‐Binding Neutralizing Antibody that Lacks a Protruding Loop (2017) (64)
- Most rhesus macaques infected with the CCR5-tropic SHIVAD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains (2012) (64)
- Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate (2005) (63)
- Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates (2013) (63)
- Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates (2021) (62)
- Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein (2008) (62)
- Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs (2015) (62)
- Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains (2013) (62)
- Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. (1998) (61)
- Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. (2019) (60)
- A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. (2000) (60)
- No Evidence for Consistent Virus-Specific Immunity in Simian Immunodeficiency Virus-Exposed, Uninfected Rhesus Monkeys (2007) (60)
- Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies (2003) (60)
- HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins (2012) (60)
- Progress in the rational design of an AIDS vaccine (2011) (59)
- Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination (2002) (59)
- Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site* (2011) (59)
- Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design (2016) (59)
- Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation (2017) (59)
- Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies (2021) (59)
- HIV-1: nature's master of disguise (2003) (59)
- The changing face of HIV vaccine research (2012) (59)
- Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity (2018) (59)
- A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice (2021) (58)
- Influence of Novel CD4 Binding-Defective HIV-1 Envelope Glycoprotein Immunogens on Neutralizing Antibody and T-Cell Responses in Nonhuman Primates (2009) (58)
- Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting (2017) (58)
- Anti-HIV B Cell Lines as Candidate Vaccine Biosensors (2012) (58)
- Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? (2009) (58)
- Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. (2006) (58)
- Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses (2011) (58)
- Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans (2012) (58)
- A Neutralizing Antibody Recognizing Primarily N‐Linked Glycan Targets the Silent Face of the HIV Envelope (2018) (57)
- Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody (2015) (56)
- Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope (1999) (56)
- Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. (2005) (56)
- Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies (2011) (55)
- Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. (2020) (55)
- A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. (2019) (55)
- Genetic subtypes of HIV-1 (1993) (55)
- Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape (2017) (54)
- A Monoclonal Antibody for Malaria Prevention. (2021) (54)
- Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. (2005) (54)
- Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization. (2013) (54)
- Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. (2018) (54)
- Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 (2010) (53)
- Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern (2021) (53)
- HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies. (2011) (53)
- Single-Cell and Deep Sequencing of IgG-Switched Macaque B Cells Reveal a Diverse Ig Repertoire following Immunization (2014) (53)
- Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4 (2018) (51)
- The TRIM5 Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys (2011) (51)
- Dendritic Cells Are Less Susceptible to Human Immunodeficiency Virus Type 2 (HIV-2) Infection than to HIV-1 Infection (2007) (50)
- Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIVAD8 in Rhesus Macaques: Implications for Use in Vaccine Studies (2012) (50)
- Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. (2019) (50)
- Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. (2012) (50)
- Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier (2018) (49)
- Longitudinal Analysis Reveals Early Development of Three MPER‐Directed Neutralizing Antibody Lineages from an HIV‐1‐Infected Individual (2019) (49)
- SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts (2016) (48)
- Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain (2009) (48)
- Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects (2021) (48)
- A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone (2020) (48)
- A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. (2016) (47)
- Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability (2016) (47)
- Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates (2021) (47)
- A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike (2020) (45)
- Lysis of Human Immunodeficiency Virus Type 1 by a Specific Secreted Human Phospholipase A2 (2006) (45)
- Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120 (2017) (45)
- Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. (1999) (45)
- Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. (2017) (45)
- Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. (2019) (45)
- Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. (2009) (45)
- Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins (2004) (44)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung (2021) (43)
- Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies (2019) (43)
- Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody That Recognizes a Novel Conformational Epitope on gp41 and Lacks Reactivity against Self-Antigens (2008) (43)
- Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody (2020) (43)
- Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 (2013) (42)
- Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. (2007) (42)
- Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody (2018) (42)
- Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus (2005) (42)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes (2020) (41)
- Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8 (2016) (41)
- N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementation of Function (2013) (41)
- Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates (2021) (41)
- Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. (2008) (41)
- Accumulation of follicular CD8+ T cells in pathogenic SIV infection (2018) (41)
- Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. (2016) (41)
- Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. (2006) (40)
- Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys (2017) (40)
- A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus (2015) (40)
- A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques (2021) (40)
- Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV (2018) (39)
- Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 (2012) (39)
- Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus (2017) (38)
- In vitro reconstitution of B cell receptor–antigen interactions to evaluate potential vaccine candidates (2016) (38)
- A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone (2020) (38)
- Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140 (1998) (38)
- Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects (2021) (38)
- Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth (2020) (37)
- Serotyping International HIV-1 Isolates by V3 Peptides and Whole GP160 Proteins Using BIAcore (1994) (37)
- Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. (2020) (37)
- Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies (2017) (36)
- Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry (2019) (36)
- Preservation of Functional Virus-Specific Memory CD8+ T Lymphocytes in Vaccinated, Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys1 (2006) (36)
- COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge (2021) (36)
- Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies (2014) (36)
- Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. (2018) (35)
- Protection of calves by a prefusion-stabilized bovine RSV F vaccine (2017) (35)
- Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants (2021) (35)
- Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys (2017) (34)
- A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice (2021) (34)
- HIV-1 entry at the mucosal surface: role of antibodies in protection. (2000) (34)
- Herpes simplex virus vaccines--why don't antibodies protect? (1999) (34)
- Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates (2012) (33)
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (33)
- Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. (2013) (32)
- Dysfunction of Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus-Induced IL-2 Expression by Central Memory CD4+ T Lymphocytes1 (2005) (32)
- Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. (2011) (31)
- Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge (2018) (31)
- Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. (2002) (31)
- Development of a potent Zika virus vaccine using self-amplifying messenger RNA (2020) (30)
- Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity (2020) (30)
- Genetic, antigenic and serologic characterization of human immunodeficiency virus type 1 from Indonesia. (1997) (30)
- Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses (2020) (30)
- Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen (2020) (30)
- Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys (2005) (30)
- The modern era of HIV-1 vaccine development (2015) (29)
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants (2021) (29)
- A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies (2020) (29)
- BLyS-Mediated Modulation of Naive B Cell Subsets Impacts HIV Env-Induced Antibody Responses (2012) (29)
- HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies (2018) (29)
- Design of epitope-specific probes for sera analysis and antibody isolation (2012) (29)
- Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting (2019) (29)
- Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial (2022) (29)
- Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. (2018) (29)
- Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. (2016) (29)
- Diverse Antibody Genetic and Recognition Properties Revealed following HIV-1 Envelope Glycoprotein Immunization (2015) (29)
- Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection (2016) (29)
- Antibodyomics: bioinformatics technologies for understanding B‐cell immunity to HIV‐1 (2017) (28)
- Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. (2003) (28)
- Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis (2015) (28)
- Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry (2019) (27)
- Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site (2016) (27)
- Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding (2016) (27)
- A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates (2019) (27)
- Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations (2019) (26)
- Enhanced Exposure of the CD 4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp 120 Domain (2009) (26)
- High-Resolution Longitudinal Study of HIV-1 Env Vaccine–Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence (2016) (26)
- Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination (2007) (26)
- Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines (2020) (25)
- HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization (2014) (25)
- Broadly neutralizing antibodies target the coronavirus fusion peptide (2022) (25)
- Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites (2013) (25)
- Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials (2015) (25)
- Broadly neutralizing antibodies target the coronavirus fusion peptide (2022) (25)
- Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotype Monoclonal Antibodies Mimicking the CD4-Binding Site (2008) (25)
- Disseminated gonococcal infection. (1992) (25)
- Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity (2017) (24)
- A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. (1998) (24)
- Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination (2004) (24)
- Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. (2001) (24)
- Immunization with Wild-Type or CD4-Binding-Defective HIV-1 Env Trimers Reduces Viremia Equivalently following Heterologous Challenge with Simian-Human Immunodeficiency Virus (2010) (24)
- Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus (2016) (24)
- Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation (2016) (23)
- Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments (2017) (23)
- Improvement of antibody functionality by structure-guided paratope engraftment (2019) (23)
- Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults (2015) (23)
- HIV/AIDS: Allied responses (2007) (23)
- Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine (2016) (23)
- Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. (2021) (23)
- Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15. (2000) (23)
- Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas (2015) (22)
- Immune checkpoint modulation enhances HIV-1 antibody induction (2020) (22)
- Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1. (2009) (22)
- Infectious causes of carpal tunnel syndrome: case report and review. (1991) (22)
- Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. (2021) (22)
- Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. (2005) (22)
- Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development (2020) (22)
- HIV and peacekeeping operations in Cambodia (1995) (21)
- Genital Tract Sequestration of SIV following Acute Infection (2011) (21)
- Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. (2020) (21)
- Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality (2020) (21)
- Q fever in US military returning from Iraq. (2007) (21)
- Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors (2018) (21)
- Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. (2018) (21)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes (2020) (21)
- Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel. (2005) (21)
- Macaque dendritic cells infected with SIV-recombinant canarypox ex vivo induce SIV-specific immune responses in vivo. (2004) (21)
- Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. (2021) (20)
- An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial (2017) (20)
- Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011) (2014) (20)
- Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction. (2000) (20)
- Exploiting glycan topography for computational design of Env glycoprotein antigenicity (2018) (20)
- Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses (2021) (20)
- Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates (2018) (20)
- Antigen detection in neutralization assays: high levels of interfering anti-p24 antibodies in some plasma. (1993) (20)
- Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials (2018) (19)
- Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains (2020) (19)
- Systemic and Mucosal T-Lymphocyte Activation Induced by Recombinant Adenovirus Vaccines in Rhesus Monkeys (2009) (19)
- Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection (2016) (18)
- A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. (2013) (18)
- AIDS vaccines. Are we ready for human efficacy trials? (1994) (18)
- Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses (2019) (18)
- Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Antibody Dilution Method. (1999) (17)
- Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial (2020) (17)
- Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies (2019) (17)
- HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques (2017) (17)
- Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. (2015) (17)
- Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models (2013) (17)
- Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques. (2011) (17)
- 147 Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 (2011) (17)
- TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption (2021) (17)
- A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. (2000) (17)
- Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B (2019) (17)
- High throughput HIV-1 microneutralization assay (2013) (15)
- Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/macaque model (2009) (15)
- Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation (2018) (15)
- Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. (2021) (14)
- A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings (2021) (14)
- Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials (2020) (14)
- Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates (2010) (14)
- Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound (2020) (14)
- VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. (2020) (14)
- T-Cell Vaccination Reduces Simian Immunodeficiency Virus Levels in Semen (2009) (14)
- Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation (2015) (14)
- Comparison of adjuvants to optimize influenza neutralizing antibody responses. (2019) (14)
- Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes (2019) (14)
- Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? (2016) (13)
- An HIV-1 Env–Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes (2016) (13)
- HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates (2017) (13)
- Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses (2020) (13)
- Changes in the V 3 region of gp 120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR 5 Delta 32 heterozygote (2007) (13)
- B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. (2021) (13)
- Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. (2022) (13)
- Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial (2022) (12)
- Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation (2018) (12)
- The Cat and Mouse of HIV-1 Antibody Escape (2009) (12)
- Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. (2015) (12)
- Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012) (2016) (12)
- Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria (2021) (12)
- 2 – IMMUNOLOGY: PART A. Basic Immunology of Vaccine Development (2003) (12)
- Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Infectivity Reduction Method. (1999) (11)
- Eliminating antibody polyreactivity through addition of N‐linked glycosylation (2015) (11)
- Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody (2021) (11)
- Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeficiency Virus Infection in Rhesus Monkeys (2009) (11)
- Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. (2022) (11)
- Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies (2013) (11)
- Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus (2020) (11)
- Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine (2019) (11)
- Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques (2019) (11)
- Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants (2021) (10)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway (2021) (10)
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial (2022) (10)
- Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. (2020) (10)
- Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation. (2020) (10)
- Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. (2019) (10)
- Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys. (2010) (10)
- Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation (2018) (10)
- Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor (2020) (10)
- LY-CoV1404 potently neutralizes SARS-CoV-2 variants (2021) (10)
- VRC01 provides sterilizing protection to non human primates from mucosal SHIV challenges (155.11) (2011) (9)
- Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. (2019) (9)
- Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials (2021) (9)
- Transmission of HIV-1 subtype E in the united states. (1996) (9)
- Envelope Variable Region 4 Is the First Target of Neutralizing Antibodies in Early Simian Immunodeficiency Virus mac251 Infection of Rhesus Monkeys (2012) (9)
- Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates (2021) (9)
- Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs (2018) (9)
- Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial (2019) (9)
- P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment (2009) (9)
- Determination of Syncytium-Inducing Phenotype of Primary HIV-1 Isolates Using MT-2 cells. (1999) (8)
- Stable Latent HIV Infection and Low-Level Viremia Despite Treatment with the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. (2021) (8)
- Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron (2021) (8)
- Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses (2022) (8)
- Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine (2021) (8)
- Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. (2022) (8)
- Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability (2022) (8)
- Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses (2021) (8)
- Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial (2014) (7)
- Demonstration of de novo HIV type 1 production by detection of multiply spliced and unspliced HIV type 1 RNA in paraffin-embedded tonsils. (2002) (7)
- Risk of HIV transmission in infected US military personnel (1996) (7)
- First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody (2022) (7)
- Blocking α4β7 integrin delays viral rebound in SHIVSF162P3-infected macaques treated with anti-HIV broadly neutralizing antibodies (2021) (6)
- TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys (2011) (6)
- HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile. (2014) (6)
- Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients (2021) (6)
- Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach (2020) (5)
- A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination (2022) (5)
- , Epitope 1 Antibody 2 F 5 in Complex with Its gp 41 Anti-Human Immunodeficiency Virus Type Structure and Mechanistic Analysis of the (2004) (5)
- Virus-Like Particle Based-Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide (2020) (5)
- Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection (2017) (5)
- Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection (2018) (5)
- Crystal structure of Middle-East Respiratory Syndrome (MERS) coronavirus neutralizing antibody JC57-14 isolated from a vaccinated rhesus macaque. (2018) (5)
- Structure-guided modification and optimization of antibody VRC07 (2012) (5)
- Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization (2021) (4)
- Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
- A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention (2021) (4)
- Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies (2020) (4)
- Author Correction: Next-generation influenza vaccines: opportunities and challenges (2020) (4)
- HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation (2016) (4)
- Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants (2021) (4)
- SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity (2021) (4)
- Engineering immune evasion (2006) (4)
- Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (4)
- The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies (2015) (3)
- Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group (2010) (3)
- Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide (2020) (3)
- Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base (2021) (3)
- CD8β Depletion Does Not Prevent Control of Viral Replication or Protection from Challenge in Macaques Chronically Infected with a Live Attenuated Simian Immunodeficiency Virus (2019) (3)
- Correction for Hraber et al., “Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments” (2018) (3)
- HIV Immunology Goes Out On a Limb. (2016) (3)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. (2020) (3)
- Limited flavivirus cross-reactive antibody responses elicited by a ZIKV DNA vaccine candidate in humans. (2021) (3)
- Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques (2021) (3)
- Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine (2022) (3)
- Neutralizing antibody quantification by flow cytometry. (2004) (3)
- Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron (2022) (3)
- Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. (2019) (2)
- Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site (2012) (2)
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis (2022) (2)
- Technical challenges and scientific issues: Genetic subtypes of HIV-1 (1993) (2)
- HIV-1 gp120–CD4-Induced Antibody Complex Elicits CD4 Binding Site–Specific Antibody Response in Mice (2020) (2)
- Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability (2016) (2)
- Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial (2023) (2)
- Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations (2019) (2)
- Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. (2022) (2)
- Structure of Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition (2019) (2)
- Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 (2012) (2)
- Longitudinal antibody responses in people who inject drugs infected with similar HIV strains. (2020) (2)
- Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies (2021) (2)
- Structural definition of a novel CD4-induced epitope that is targeted by a single-headed immunoglobulin to effect broad and potent HIV neutralization (2012) (2)
- Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition. (2022) (2)
- Editorial overview: Vaccines: Vaccines for cancer and infectious diseases. (2015) (2)
- Structural survey of HIV-1-neutralizing antibodies targeting Env trimer delineates epitope categories and suggests vaccine templates (2018) (2)
- Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings (2022) (2)
- Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases (2019) (2)
- Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention (2022) (2)
- A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape (2022) (2)
- Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes (2021) (1)
- CHAPTER 8 – The Design of a Global AIDS Vaccine (2008) (1)
- Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120 (2012) (1)
- Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. (2023) (1)
- Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope (2006) (1)
- Design of nanoparticulate group 2 influenza hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages (2018) (1)
- Correction for Acharya et al., Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites (2014) (1)
- Germline-targeting and Reverse Engineering to Elicit CH235.12 Lineage bNAbs (2018) (1)
- Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2 (2022) (1)
- Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates (2014) (1)
- Track A Basic Science (2012) (1)
- Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals (cid:1) (2008) (1)
- An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults (2023) (1)
- Extensive CD8β depletion does not prevent control of viral replication or protection from challenge in macaques chronically infected with a live attenuated simian immunodeficiency virus (2019) (1)
- Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
- Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses (2022) (1)
- Amarendra Pegu than those to the CD 4 receptor Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo (2014) (1)
- Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life (2022) (1)
- 116 Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection (2012) (1)
- An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans (2023) (1)
- Determination of HIV-1 Chemokine Coreceptor Tropism Using Transduced Human Osteosarcoma (HOS) Cells. (1999) (1)
- Author Correction: Next-generation influenza vaccines: opportunities and challenges (2020) (1)
- Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models (2013) (1)
- A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization (2022) (1)
- Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial (2022) (1)
- Vaccination Induces Maturation of Diverse Unmutated VRC01-Class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-Humanized Mouse Model (2020) (1)
- Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. (2022) (1)
- Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability (2022) (1)
- Power to Detect HIV Vaccine Effects in Repeated Low-Dose Challenge Experiments (2009) (1)
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114: A Phase 1 Trial of a Therapeutic Monoclonal Antibody Targeting Ebola Virus Glycoprotein (2019) (1)
- Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology (2012) (1)
- HIV-1 neutralizing antibodies display dual specificity for the primary and coreceptor binding sites and preferential recognition of fully-cleaved Env (2012) (1)
- Delay in viral rebound with TLR7 agonist, N6-LS and PGT121 in SHIV-infected macaques (2019) (1)
- P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011) (2009) (1)
- Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
- OA05-05. Impact of in vivo CD4 binding during HIV-1 Env trimer immunizations of rhesus macaques (2009) (1)
- Deep sequencing with longitudinal sampling of a VRC01-like-antibody response in a chronically infected individual (2012) (1)
- Vaccine-elicited cross-neutralizing HIV antibodies directed to multiple sites of Env vulnerability following heterologous NFL trimer-liposome prime:boosting (2019) (0)
- Crystal Structure of the broadly neutralizing anti-HIV-1 antibody 2F5 in complex with a gp41 11mer epitope (2004) (0)
- Running Title: Specific inhibition of HIV-1 by human group X sPLA2 (2006) (0)
- Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01 (2012) (0)
- T-Cell Vaccination Reduces Simian Immunodeficiency Virus Levels in Semen (cid:1) (2009) (0)
- Crystal structure of the broadly neutralizing Influenza A antibody VRC 315 02-1F07 Fab. (2017) (0)
- An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial (2017) (0)
- Cross Neutralization of Hiv-1 Isolates from Northern Thailand and the United States in a Human Peripheral Blood Mononuclear Cell Assay (1993) (0)
- Human immunodeficiency virus type 1 candidate vaccine breakthrough infection. (1995) (0)
- Potent vaccine sera target epitopes that overlap the CD4 binding site. (2015) (0)
- Crystal structure of anti-HIV llama VHH antibody A12 (2012) (0)
- Crystal structure of multidonor HV6-1-class broadly neutralizing Influenza A antibody 56.a.09 in complex with Hemagglutinin Hong Kong 1968. (2016) (0)
- Design of epitope-specific probes for sera analysis and antibody isolation (2012) (0)
- Next-generation influenza vaccines: opportunities and challenges (2020) (0)
- Potent SIV-specific Antibodies Targeting the Cyanovirin Binding Site (2014) (0)
- Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1 (2022) (0)
- N-linked Glycosylation of HIV-1 core gp120 is Not Required for Native Trimer Formation or Viral Infectivity (2014) (0)
- A Structure-Based Matrix Approach Yields Improved VRC01-Class Antibodies for HIV-1 Therapy and Prevention (2020) (0)
- Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency (2023) (0)
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness (2020) (0)
- Protection against repeated vaginal SHIV challenges by a combination of VRC01 and an anti-α4β7 antibody (2018) (0)
- Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials (2020) (0)
- Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones (2022) (0)
- Overview of human plasmas and animal sera. (2015) (0)
- P16-28. The first year: early correlates of long-term HIV progression (2009) (0)
- Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 (2018) (0)
- Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 1) (2015) (0)
- of Neutralizing Antibodies HIV-1 Env Pseudoviruses for Assessment Tiered Categorization of a Diverse Panel of (2013) (0)
- Correction for Ingale et al., Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies (2015) (0)
- Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. (2021) (0)
- ResponsesImpacts HIV Env-Induced Antibody BLyS-Mediated Modulation of Naive B Cell (2017) (0)
- HIV and peacekeeping operations in Cambodia [letter] (1995) (0)
- Title: Immune Correlates of Protection by mRNA-1273 Immunization against 1 SARS-CoV-2 Infection in Nonhuman Primates (2021) (0)
- Crystal structure of murine 2D5 Fab, a potent anti-CD4 HIV-1-neutralizing antibody in complex with CD4 (2014) (0)
- Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein (cid:1) † (2008) (0)
- IgG-Switched Macaque B Cells Reveal a Single-Cell and Deep Sequencing of Karlsson Hedestam (2014) (0)
- Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01 (2012) (0)
- Zinc Acetate / Carrageenan Gel ( PC-1005 ) (2014) (0)
- Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. (2019) (0)
- Structure-guided modification and optimization of antibody VRC07 (2012) (0)
- Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeficiency Virus Infection in Rhesus Monkeys (cid:1) (2009) (0)
- Crystal structure of multidonor HV6-1-class broadly neutralizing Influenza A antibody 56.a.09 isolated following H5 immunization. (2016) (0)
- Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies (2012) (0)
- Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones (2022) (0)
- As antibody findings mount, what comes next? Interview by Kristen Jill Kresge and Regina McEnery. (2011) (0)
- Crystal structure of broadly neutralizing VH1-46 germline-derived CD4-binding site-directed antibody CH235.09 in complex with HIV-1 clade A/E 93TH057 gp120 (2016) (0)
- Crystal structure of ligand-free VRC03 antigen-binding fragment. (2016) (0)
- ST102 Structural Basis for Broad and Potent HIV-1 neutralization by CD4-mimetic miniproteins (2013) (0)
- Crystal structure of HIV-gp120 core in complex with CD4-binding site antibody b13, space group C2221 (2009) (0)
- 454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8 (2012) (0)
- Crystal structure of human Fab CAP256-VRC26.25, a potent V1V2-directed HIV-1 broadly neutralizing antibody (2014) (0)
- Crystal structure of 10E8 gHV-gLV antigen-binding fragment. (2016) (0)
- Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity (2020) (0)
- Partial germline reversions can increase VRC07 potency and breadth (2012) (0)
- Crystal structure of multidonor HV1-18+HD3-9 class broadly neutralizing Influenza A antibody 31.b.09 in complex with Hemagglutinin H1 A/California/04/2009 (2016) (0)
- Crystal structure of HIV-1 donor 45 d45-01dG5 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995) (2015) (0)
- Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations (2017) (0)
- Applications of high-throughput single B-cell sequencing to accelerate rational vaccine design (2016) (0)
- Early prophylaxis impact for newborns at risk for HIV-1 transmission at birth: viral clearance and attenuation with neutralizing monoclonal antibodies in infant rhesus macaques (2016) (0)
- Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses (2020) (0)
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Preview (2020) (0)
- Crystal structure of VRC03 gHVgLV antigen-binding fragment. (2016) (0)
- Crystal structure of a generation 4 influenza hemagglutinin stabilized stem in complex with the broadly neutralizing antibody CR6261 (2015) (0)
- Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity (2018) (0)
- Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation (2018) (0)
- Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with TS-II-224 (2012) (0)
- Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials (2021) (0)
- Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability (2022) (0)
- Tri-functional T-cell engagers target immune checkpoint inhibitors PD-1 and TIGIT to enhance CD8 effector T-cell functions in chronically SHIV-infected rhesus macaques (2020) (0)
- Fab fragment of HIV vaccine-elicited CD4bs-directed antibody, GE356, from a non-human primate (2014) (0)
- Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology (2012) (0)
- HIV-1 splice variants and subtype analysis in formalin-fixed, paraffin-embedded tonsils from infected patients (2001) (0)
- Envelope Glycoprotein Immunization Properties Revealed following HIV-1 Diverse Antibody Genetic and Recognition (2015) (0)
- Molecular Dissection Of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination (2020) (0)
- Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men (2018) (0)
- Structure of unbound MERS-CoV spike receptor-binding domain (England1 strain). (2015) (0)
- Early Apoptotic Changes in the Leukocytes of Rhesus Macaques Challenged With Chimeric Simian/Human Immunodeficiency Virus (Shiv) (1999) (0)
- Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2 (2021) (0)
- 1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals (2019) (0)
- Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization (2023) (0)
- Potent Anti-Viral Activity of a Trispecific HIV Antibody in SHIV-Infected Monkeys (2021) (0)
- Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120 (2012) (0)
- Crystal structure of multidonor HV1-18-class broadly neutralizing Influenza A antibody 16.a.26 in complex with A/Hong Kong/1-4-MA21-1/1968 (H3N2) Hemagglutinin (2016) (0)
- Immune checkpoint modulation enhances HIV-1 antibody induction (2020) (0)
- Immunized with Oligomeric gp160 Respiratory Tracts of Mice Intranasally HIV-1 Neutralizing Antibodies in the Genital and (1998) (0)
- Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies (2019) (0)
- Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen (2020) (0)
- NIH Announces 15 Clinical and Translational Science Awards (2014) (0)
- Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 A149C-Y458C, S46G-E92D-S215P-K465Q variant. (2016) (0)
- Safety and Immunogenicity of DNAVaccines Encoding Ebolavirus and Marburgvirus Wild- Type Glycoproteins in a Phase I Clinical Trial (2015) (0)
- Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice (2022) (0)
- P-D3 Crystal structures of small-molecules HIV-1 entry ihibitor, BMS-378806 and BMS-626529, bound to BG505 SOSIP.664 HIV-1 Env trimer reveal an allosteric competitive etry inhibition mechanism (2017) (0)
- Influence of Novel CD4 binding-defective HIV-1 Envelope Glycoprotein Immunogens on Neutralizing Antibody and T Cell Responses in Non- human Primates Running title: Novel CD4 binding-defective HIV-1 Env immunogens (2009) (0)
- Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection (2015) (0)
- Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4 (2022) (0)
- Hiv-1 env fusion peptide immunogens and their use (2017) (0)
- Reverted to Germline with Ig-Framework Regions Substantially HIV-1 with High Breadth and Potency Even Antibodies VRC01 and 10E8 Neutralize (2014) (0)
- Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 2) (2015) (0)
- Neutralizing Activ ity of Zika Virus-Immune Sera Identifies a Single Viral Serotype Graphical (0)
- Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 (cid:1) †§ (2011) (0)
- Trispecific antibody against HIV-1 demonstrate anti-viral activity in vivo and have potent Fc-dependent effector functions (2020) (0)
- Subsets Impacts HIV Env-Induced Antibody BLyS-Mediated Modulation of Naive B Cell Cancro and (2012) (0)
- HIV broadly neutralizing antibodies and immunological tolerance (VAC7P.988) (2014) (0)
- Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells (2002) (0)
- B-111 Sulfotyrosine-mediated V2-V3 interaction stabilizes the HIV-1 envelope trimer facilitating immune evasion (2016) (0)
- Improvement of antibody functionality by structure-guided paratope engraftment (2019) (0)
- P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys (2009) (0)
- Crystal structure of 10E8 gHV-matureL antigen-binding fragment. (2016) (0)
- Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies (2012) (0)
- Improving Antibody Discovery and Selection Techniques Moderator: David King, Chief Scientific Officer, AnaptysBio 8:00 Isolation and Deep Sequencing of HIV-1 Neutralizing Antibodies (2012) (0)
- Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys (cid:1) (2011) (0)
- Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (0)
- Post-exposure treatment with neutralizing monoclonal antibodies prevents SHIV infection in infant rhesus macaques and limits establishment of latent viral reservoirs (VAC11P.1102) (2015) (0)
- Isolation of Monoclonal Antibodies from a SHIV-AD8 Infected Rhesus Macaque with Broad Neutralizing Activity (2014) (0)
- Critical determinants in the emergence of broadly neutralizing CD4-binding site antibodies from an HIV-1-infected Chinese donor (2016) (0)
- D-106 Tyrosine Sulfation in the Second Variable Domain (V2) of gp120 Regulates HIV-1 Sensitivity to Neutralization (2014) (0)
- Crystal structure of anti-HIV llama VHH antibody A12 in complex with C186 gp120 (2012) (0)
- Novel vaccine technologies for the 21st century (2019) (0)
- Exploration ofAntigenic Variation ingpl20 fromClades A through FofHumanImmunodeficiency Virus Type1by UsingMonoclonal Antibodies (1994) (0)
- A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies (2012) (0)
- Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture (2012) (0)
- Preexposure passive transfer predicts plasma antibody levels prevent HIV-I aquisition (2014) (0)
- Rapid development of a DNAvaccine for Zika virus (2016) (0)
- Crystal structure of Middle-East Respiratory Syndrome (MERS) coronavirus neutralizing antibody JC57-14 isolated from a vaccinated rhesus macaque in complex with MERS Receptor Binding Domain (2018) (0)
- Novel antibodies with broad neutralizing power of HIV-1 (2011) (0)
- Antibodiesand Their Recognition by Immunotypes of a Quaternary Site of HIV-1 (2014) (0)
- Passive infusion of Fc-modified neutralizing antibodies does not affect the dynamics of plasma virus decay in SHIV-infected macaques (2019) (0)
- P-C17 Critical role of V2 Sulfotyrosines in Stabilizing the HIV-1 Envelope Trimer in its Closed, Antibody-Protected Conformation (2017) (0)
- Protection of rhesus macaques against vaginal SHIV challenges by VRC01 and an anti-α4β7 antibody (2018) (0)
- I-101 Quaternary contact improves the potency of broadly neutralizing antibodies to the CD4-binding site of HIV-1 (2019) (0)
- Structural definition of a novel CD4-induced epitope that is targeted by a single-headed immunoglobulin to effect broad and potent HIV neutralization (2012) (0)
- Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses (2021) (0)
- Partial germline reversions can increase VRC07 potency and breadth (2012) (0)
- Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates (2012) (0)
- Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site (2012) (0)
- Isolation and Characterization of Cross-Neutralizing COVID-19+ Subjects (2021) (0)
- Commentary The changing face of HIV vaccine research (2012) (0)
- HIV-Specific Antibodies Mediate Rapid Antibody-Dependent Cellular Cytotoxicity Against Primary HIV-Infected CD4+T Cells (2010) (0)
- Crystal structure of vaccine-elicited pan- influenza H1N1 neutralizing murine antibody 441D6. (2018) (0)
- P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys (2009) (0)
- HIV-1 neutralizing antibodies display dual specificity for the primary and coreceptor binding sites and preferential recognition of fully-cleaved Env (2012) (0)
- Quantitative, molecular-level analysis of the serum antibody repertoire reveals unanticipated features of the response to seasonal influenza vaccination (2016) (0)
- Crystal structure of vaccine-elicited broadly neutralizing VRC01-class antibody 2411a in complex with HIV-1 gp120 core (2021) (0)
- E-101 Preventative HIV Vaccine Progress (2014) (0)
- A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies (2012) (0)
- A meta-analysis of passive immunization studies shows an association of serum neutralizing antibody titer with protection against SHIV challenge (2019) (0)
- Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (0)
- Rhesus macaque Bcl-6/Bcl-xL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node. (2023) (0)
- Protection of calves by a prefusion-stabilized bovine RSV F vaccine (2017) (0)
- Crystal structure of broadly neutralizing Influenza A antibody 31.a.83 in complex with Hemagglutinin Hong Kong 1968. (2017) (0)
- Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses (2022) (0)
- Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture (2012) (0)
- Neutralizing Antibodies Afforded by Passive Infusion of Does Not Augment the Sterile Protection Immunodeficiency Virus DNA Vaccination Immunodeficiency Virus Type 1 / Simian Cellular Immunity Elicited by Human (2003) (0)
- Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 (2012) (0)
- Crystal structure of HIV-1 93TH057 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995) (2015) (0)
- 126 Broadly Neutralizing HIV Abs: Gains and Losses in Translation (2012) (0)
- Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues (2021) (0)
- , In Vivo Infection Improves Protection against Lentiviral In Vitro Neutralizing HIV-1 Antibody Enhanced Potency of a Broadly (2014) (0)
- 454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8 (2012) (0)
- Variable Dependence on Glycan Recognition within a Lineage of V1V2-directed HIV Neutralizing Antibodies (2014) (0)
- Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 A149C-Y458C variant. (2016) (0)
- Antibody VRC 01 Structural Basis for Broad and Potent Neutralization of HIV-1 by (2014) (0)
- Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2 (2022) (0)
- Sundling the HIV Primary Receptor Binding Site High-Resolution Definition of Vaccine-Elicited B Cell Responses Against (2012) (0)
- Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition (2022) (0)
- Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized Trials (2021) (0)
- A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage (2019) (0)
- Vaccine reactions (1998) (0)
- Serum recognition of the native trimer and effects of a key mutation in the CD4 binding loop. (2015) (0)
- Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates (2012) (0)
- Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 variant. (2016) (0)
- Deep sequencing with longitudinal sampling of a VRC01-like-antibody response in a chronically infected individual (2012) (0)
- Crystal structure of vaccine-elicited broadly neutralizing VRC01-class antibody 2413a in complex with HIV-1 gp120 core (2021) (0)
- Structure of HIV-1 gp120 (core with V3) in Complex with CD4-Binding-Site Antibody F105 (2009) (0)
This paper list is powered by the following services:
Other Resources About John R. Mascola
What Schools Are Affiliated With John R. Mascola?
John R. Mascola is affiliated with the following schools:
